

Debenhams: Cash Flow and Dividend Worries

Analyst: James Armstrong

[Debenhams – Notes and Models](#)

Recommendation: Short (No Change)

Price: 80p / **2 Year Price Target:** 42p / **Forecast Return:** -48%

Ticker: DEB LN / **Market Cap:** £982m / **3m Average Daily Volume (USD):** \$3m

Valuation Metric: PE FY18e / **Current Multiple:** 19x / **Target Multiple:** 10x

Investment Thesis:

- Structurally-challenged retailer with stagnant revenues and falling margins, entering a more difficult period for UK consumers.
- Free cash flow inflated by working capital, lease incentive inflows and low cash tax totaling £105m since H1'14, representing 36% of total free cash flow in that period.
- We estimate profits to fall 40% from FY15 to FY18, dividend to be uncovered from FY17 onwards.
- Valuation at 10x FY18 earnings with dividend cut likely as lease adjusted net debt to EBITDA multiple approaches 5x.

We update our Short thesis on Debenhams following the recent H1'16 report. Results in the period are not as good as the headline figures suggest and cash flows have been inflated through working capital, lease incentives and cash tax paid running below the accounting tax expense. These positive cash movements are non-recurring and in combination with weakening trading we see the FY17 dividend being uncovered by free cash flow and susceptible to a cut. We would therefore continue to short the shares based on a 42p price target which is 10x FY18 estimated earnings.

Recent Results & Cash Flow Concerns

The recent H1'16 results were Michael Sharp's last set of figures before leaving the company. The headlines look OK, but if we dig a little deeper into sales and cash flow the results are not so good for the incoming chief executive – who has yet to be identified:

- UK in-store sales increased by 0.1%, the first such increase in four years. However, this refers to gross transaction value ("GTV"), which is the total of all sales made by both Debenhams and concession partners – **this is not revenue! Overall GTV for the whole company increased by 1.6%, but revenue by only 0.1% - so in fact UK store revenues likely fell in the period.** This difference comes from the rising proportion of sales by concession partners as surplus space in UK stores is allocated to them, and this difference will continue for the foreseeable future. Concession space operates at a lower margin than own-utilised space, therefore we expect margins in the medium term to fall.

- EBIT margins in the period were actually flat on H1'15 at 7.5%, suggesting a good result. However this has been achieved through a dramatic reduction in the levels of discounting. This step can only be achieved once. We expect core pricing will need to be reduced further to compete with rivals and, combined with the rising proportion of concessions sales, margins will once again resume their downward trend.
- Free cash flow performance appears impressive at £126m vs £94m in H1'15, and the company announced a 2.5% dividend increase. However, we need to look carefully at the reasons for this increase:
 - £11.2m one-off cash inflow from closing forex contracts – this is non-recurring.
 - £15m working capital inflow.
 - £9m inflow from lease incentives
 - £16m benefit from cash tax being lower than the accounting tax expense.

The “sustainable” free cash flow for the half is therefore £74m, not £126m.

- Looking at these movements in more depth since H1'14, we see that of the £289m of free cash flow since H1'14, only £185m (64%) of it has come from underlying trading and can therefore be deemed sustainable in the long term.

Exhibit 1: Influences on Free Cash Flow

Source of cash movement	H1'14	H2'14	H1'15	H2'15	H1'16	Total
	£m	£m	£m	£m	£m	£m
Working capital	-14	25	13	-8	15	31
Other non current liabilities	5	6	-1	9	9	28
Tax charge per accounts	-17	-2	-17	-3	-17	
Tax paid	-16	-5	1	1	-2	
Net tax impact on cash flow	1	-3	18	3	16	35
Derivative contracts					11	11
Total impact on free cash flow	-8	28	30	4	51	105
Actual free cash flow in period	51	28	94	-10	126	289
Of which from underlying trading	59	1	64	-14	74	185


Source: Company figures

So, in summary, business performance was weaker than at first glance in what has been a buoyant environment in recent years for UK consumers and the improvement in the debt position has come largely from one-off cash flow items rather than sustainably good business performance.

Poor Trading Conditions

The consumer environment is now weakening and, in particular, spending on clothing is falling after two years of growth in 2014 and 2015. M&S, Next and N Brown have already warned of the tough environment with strong price competition. The weakest operators have had a stay of execution in recent years but their luck is now running out. BHS, with around 160 UK stores, is today filing for administration as its department store model has failed to keep up with changing consumer trends. Austin Reed, the menswear retailer, is also expected to appoint administrators shortly. We expect that Debenhams will also suffer in the next few months.

Exhibit 2: ONS Textile, Clothing & Footwear Stores sales and volumes (seasonally adjusted)



Source: ONS

Estimates and Dividend Issues

We forecast flat revenues for the next three years, which combined with an EBIT margin falling from 5.8% to 3.5% means that we expect EBIT to fall from £134m in FY15 to £81m in FY18. This translates to profit after tax falling from £93m to £51m over the same period.

Free cash flow is likely to plummet, and we see free cash flow conversion falling well-below 100%. Capex of around £130m in FY16 is higher than D&A of approximately £110m and we expect this trend to continue as the business still needs to invest heavily in bringing its store estate up to date. The company will no longer get a working capital benefit going forward as stock levels cannot be reduced further and supplier payables cannot be stretched any further. Meanwhile there should be no further inflows of lease incentives for the next two years as no new stores will be opened in that time.

We estimate free cash flow of £35m in FY17 and £23m in FY18. The dividend would then be uncovered in both years and we see the lease adjusted net debt to EBITDAR ratio increasing from around 4.5 to 4.9x. This would be slightly below the level reached in FY08 before the last rights issue. The prospect of a dividend cut in the next two years is therefore very real.

Conclusion

We value the business at 10x FY18e earnings, the low multiple due to the horrendous balance sheet and 22 years of off-balance sheet lease liabilities which gives the company little leeway if the business deteriorates further.

Clients may ask why we dropped our Short recommendation on [N Brown](#) after the recent warning and yet retain our recommendation on Debenhams. **The big difference compared to N Brown is the much greater vulnerability of the Debenhams dividend.** At present the Debenhams dividend is covered by free cash flow but N Brown is not. However, we see the Debenhams dividend being uncovered by FY17. N Brown's debt is more than covered by its customer loan book and it can therefore continue to finance an uncovered dividend from more debt. Debenhams does not have this ability.

We therefore retain our Short recommendation with a slightly reduced price target of 42p, giving 48% downside from here.

Important Information and Disclaimers

The accompanying documents have been prepared and issued by The Analyst Research LLP ("The Analyst"). The Analyst is a limited liability partnership authorised and regulated by the Financial Conduct Authority ("FCA") of the United Kingdom (firm reference number 605593) and registered as an investment adviser in the United States of America by the U.S. Securities and Exchange Commission (registration number 801-76777). Registered office: Arthur House, Chorlton Street, Manchester, M1 3FH. Trading address: 35 Bedford Road, London, SW4 7EF.

THE ACCOMPANYING DOCUMENTS ARE MARKETING COMMUNICATIONS. The documents are not independent investment research, and have not been prepared in accordance with legal requirements designed to promote the independence of investment research and, in producing these documents, The Analyst is not, and has not been, subject to any prohibition on dealing ahead of the dissemination of these documents.

The accompanying documents are intended only to promote the investment research and related advisory services of The Analyst, by using examples and case-studies to give potential clients of The Analyst a sample of The Analyst's investment research services and how such services will be provided. The examples used may be actual investment research issued previously and/or research in relation to hypothetical situations.

WITHOUT PREJUDICE TO THE FOREGOING, THESE MARKETING DOCUMENTS DO NOT RECOMMEND OR SUGGEST ANY INVESTMENT STRATEGY, DO NOT EXPRESS A CURRENT INVESTMENT RECOMMENDATION, DO NOT EXPRESS THE VIEWS OF THE ANALYST AS TO THE CURRENT OR FUTURE PRICE OF ANY INVESTMENT, AND MUST NOT BE TREATED AS DOING SO BY RECIPIENTS OF THIS DOCUMENT.

The accompanying documents are issued by The Analyst only to and/or are directed only at (and The Analyst's services will be made available only to) persons who are "professional clients" or "eligible counterparties" (as defined in the rules of the FCA). Persons of any other description (including, without limitation, persons who are "retail clients" for the purposes of the FCA Rules) must not act or rely on this material, and the services of The Analyst will not be available to such persons.

All content within these marketing documents (including text, trademarks, illustrations, photographs, graphics, designs, arrangements etc.) are protected by copyright and other protective laws. The marketing documents should not be passed on, duplicated nor reproduced in whole or in part under any circumstances without The Analyst's express written consent.

The information in the accompanying documents is provided for information purposes only and is not comprehensive. These accompanying documents are not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation which would subject The Analyst to any registration or licensing requirement within such jurisdiction. The financial instruments described in these accompanying documents research may not be eligible for sale in all jurisdictions or to certain categories of investors.

The Analyst gives no undertaking that it will update any of the information, data and opinions in this document. The Analyst may at its discretion decide to provide you with further data or material, but makes no representation that such further data or material will be calculated or produced on the same basis, or in the same format, as this material.

The Analyst's methodology for determining valuations and price targets may include, but are not restricted to, the following methodologies: analyses of market risk, growth rate, revenue stream, discounted cash flow ("DCF"), earnings before interest, tax, depreciation and amortisation ("EBITDA"), earnings per share ("EPS"), cash flow ("CF"), free cash flow ("FCF"), enterprise value ("EV")/EBITDA, price-earnings ratio ("PE"), PE/growth, price/CF, price/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group PE, sum-of-the-parts ("SOTP"), net asset value ("NAV"), dividend returns and return on equity ("ROE").

The investments described in the accompanying documents place an investor's capital at risk (i.e. an investor might lose some or all of the amount invested). Past performance is not necessarily a guide to future performance and an investor may not get back the amount originally invested. The price, value of, and income from, any of the financial instruments mentioned can rise as well as fall and may be affected by changes in economic, financial and political factors. The accompanying documents do not seek to provide an exhaustive statement of the risks associated with the investments or types of investments referred to. All information is provided AS IS with no warranties, and confers no rights. If a financial instrument is denominated in a currency other than the investor's home currency, a change in exchange rates may adversely affect the price of, value of, or income derived from the financial instrument described in this report. In addition, investors in securities such as American Depositary Receipts ("ADR's"), whose values are affected by the currency of the underlying security, effectively assume currency risk. Please note that in particular the bases and levels of taxation may change.

Any prices stated in this research are for information purposes only and do not represent valuations for individual securities or other instruments. There is no representation that any transaction can or could have been effected at those prices. Different assumptions, made by The Analyst or any other source, may yield substantially different results. The accompanying documents are intended to be for information and marketing purposes only and are not intended to constitute, and should not be construed as, investment advice. These documents have no regard for the specific investment objectives, financial situation or needs of any person. Recipients of these documents should seek their own independent financial advice. They are not and should not be construed as a recommendation, offer or solicitation for the purchase or sale of any financial instrument.

No liability is accepted by The Analyst for the reliability, accuracy or completeness of such information. In no event will The Analyst be liable to any person for any direct, indirect, special or consequential losses or damages of any kind arising out of any use of or reliance on the information in the accompanying documents, including without limitation, any loss of profit, business interruption, loss of programs or data on your equipment or otherwise. This does not exclude or restrict any duty or liability that The Analyst has to its customers under the relevant regulatory systems.